Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
SLP 
Simulations Plus Inc (SLP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/26/2025: SLP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $22.33
1 Year Target Price $22.33
| 5 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.28% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 377.91M USD | Price to earnings Ratio - | 1Y Target Price 22.33 |
Price to earnings Ratio - | 1Y Target Price 22.33 | ||
Volume (30-day avg) 6 | Beta 1.17 | 52 Weeks Range 12.39 - 37.67 | Updated Date 12/29/2025 |
52 Weeks Range 12.39 - 37.67 | Updated Date 12/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.22 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-12-01 | When - | Estimate 0.1 | Actual 0.1 |
Profitability
Profit Margin -81.74% | Operating Margin (TTM) 3.2% |
Management Effectiveness
Return on Assets (TTM) 2.74% | Return on Equity (TTM) -42.13% |
Valuation
Trailing PE - | Forward PE 21.83 | Enterprise Value 346175020 | Price to Sales(TTM) 4.77 |
Enterprise Value 346175020 | Price to Sales(TTM) 4.77 | ||
Enterprise Value to Revenue 4.37 | Enterprise Value to EBITDA 23.54 | Shares Outstanding 20144564 | Shares Floating 16664389 |
Shares Outstanding 20144564 | Shares Floating 16664389 | ||
Percent Insiders 17.26 | Percent Institutions 79.05 |
Upturn AI SWOT
Simulations Plus Inc
Company Overview
History and Background
Simulations Plus Inc. was founded in 1996. It is a leading provider of modeling and simulation software for the pharmaceutical and biotechnology industries. Over the years, the company has evolved to offer a comprehensive suite of tools that aid in drug discovery, development, and regulatory submission.
Core Business Areas
- Pharmacokinetics, Pharmacodynamics, and Drug Metabolism (PK/PD/DM): Provides software solutions for predicting drug absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties. This segment is crucial for early-stage drug discovery and optimization.
- Drug Discovery and Development Platforms: Offers integrated platforms that allow scientists to design, simulate, and analyze various aspects of drug development, from molecular design to clinical trial simulation. This includes tools for formulation development and manufacturing.
- Regulatory Consulting and Services: While primarily a software provider, Simulations Plus also offers expert consulting services leveraging their software expertise to assist clients with regulatory submissions and strategic decision-making.
Leadership and Structure
Simulations Plus Inc. is a publicly traded company with a dedicated executive leadership team responsible for strategic direction and operational management. The company is structured into divisions that align with its core business areas, fostering specialization and innovation.
Top Products and Market Share
Key Offerings
- Product Name 1: ADMET Predictoru00ae: A flagship product that uses advanced computational methods to predict a wide range of ADMET properties for small molecules. It is used by major pharmaceutical companies worldwide. Competitors include Schru00f6dinger, Certara, and others offering cheminformatics and ADMET prediction tools. Specific market share data is not publicly disclosed but it is considered a leader in its niche.
- Product Name 2: Simcypu00ae Simulator: A physiologically-based pharmacokinetic (PBPK) modeling and simulation software that allows for the prediction of drug behavior in humans and various populations. It is a widely adopted tool in the pharmaceutical industry. Competitors include Certara (Phoenix NLME, PKPlus), and various internal modeling groups. Again, specific market share is not disclosed but it is a dominant player in PBPK simulation.
- Product Name 3: GastroPlusu2122: Software for modeling and simulating drug absorption, pharmacokinetics, and pharmacodynamics, with a focus on oral drug delivery and formulation. Competitors include Certara and other formulation modeling software providers. It is a specialized tool with a strong user base.
Market Dynamics
Industry Overview
The pharmaceutical and biotechnology industries are heavily reliant on advanced computational tools for drug discovery and development to reduce costs, accelerate timelines, and improve success rates. The demand for predictive modeling and simulation software is driven by the increasing complexity of drug candidates and stringent regulatory requirements.
Positioning
Simulations Plus Inc. is positioned as a leader in the specialized field of physiologically-based modeling and simulation, and ADMET prediction. Its competitive advantages include its proprietary algorithms, extensive scientific expertise, and a strong track record of innovation and customer support. The company has built a reputation for providing reliable and scientifically validated software solutions.
Total Addressable Market (TAM)
The TAM for drug discovery and development software, including modeling and simulation tools, is substantial and growing. While specific TAM figures for the niche of PBPK and ADMET prediction are hard to isolate, the broader pharmaceutical R&D spending provides a significant market. Simulations Plus Inc. holds a strong position within its specific segments, catering to a significant portion of the pharmaceutical and biotech R&D sector.
Upturn SWOT Analysis
Strengths
- Proprietary and scientifically validated software algorithms.
- Strong reputation and established customer base in the pharmaceutical and biotech industries.
- Deep scientific expertise and experienced leadership team.
- Recurring revenue model from software subscriptions and maintenance.
- Consistent innovation and product development.
Weaknesses
- Niche market focus, making it susceptible to shifts in pharmaceutical R&D priorities.
- Reliance on a relatively small number of key products.
- Potential for larger, more diversified software companies to enter or expand in the market.
- Long sales cycles typical for enterprise software in the life sciences.
Opportunities
- Expansion into new therapeutic areas and emerging drug modalities (e.g., biologics, gene therapy).
- Increasing adoption of AI and machine learning in drug discovery, which can be integrated into their platforms.
- Growth in emerging markets with increasing pharmaceutical R&D investments.
- Partnerships with academic institutions and contract research organizations (CROs).
- Acquisition of complementary technologies or companies.
Threats
- Intensifying competition from both established software providers and new entrants.
- Changes in regulatory requirements or guidelines that may impact software needs.
- Economic downturns affecting pharmaceutical R&D budgets.
- Cybersecurity threats and data breaches.
- Development of alternative in-vitro or in-vivo testing methods that reduce reliance on simulation.
Competitors and Market Share
Key Competitors
- Certara Inc. (CETRA - not a direct publicly traded US stock symbol, but a major competitor)
- Schru00f6dinger, Inc. (SDG) - Primarily focused on physics-based computational drug discovery
- Elsevier (part of RELX PLC) - Offers data and software solutions for life sciences
Competitive Landscape
Simulations Plus Inc. has strong advantages in its deep specialization in PBPK and ADMET modeling, which are critical for many stages of drug development. Its competitors often offer broader suites of tools, but Simulations Plus's focused expertise and validated scientific models provide a competitive edge. However, larger companies like Schru00f6dinger have significant resources for R&D and market expansion.
Growth Trajectory and Initiatives
Historical Growth: Simulations Plus Inc. has experienced significant historical growth, fueled by the increasing adoption of its specialized software within the pharmaceutical and biotechnology sectors. This growth has been characterized by steady revenue increases and expansion of its product portfolio.
Future Projections: Analyst projections generally indicate continued growth for Simulations Plus Inc., driven by the ongoing need for efficient and effective drug discovery and development tools. The company is expected to benefit from industry trends favoring computational approaches and the ongoing pipeline of new drug development.
Recent Initiatives: Recent initiatives likely include further development of AI/ML integration into existing platforms, potential expansion into new software modules or product lines, and strategic partnerships to broaden market reach and enhance product capabilities.
Summary
Simulations Plus Inc. is a well-established leader in specialized pharmaceutical modeling and simulation software. Its core strengths lie in its scientifically validated products and strong customer relationships. The company benefits from a growing industry need for its solutions. However, it must remain vigilant against competition and adapt to evolving R&D paradigms in the life sciences.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations
- Financial News Outlets (e.g., Bloomberg, Reuters)
- Industry Analyst Reports
- SEC Filings (10-K, 10-Q)
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Stock market performance can be volatile, and investors should conduct their own due diligence before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Simulations Plus Inc
Exchange NASDAQ | Headquaters Research Triangle Park, NC, United States | ||
IPO Launch date 1997-06-18 | CEO - | ||
Sector Healthcare | Industry Health Information Services | Full time employees 212 | Website https://www.simulations-plus.com |
Full time employees 212 | Website https://www.simulations-plus.com | ||
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.